


## CLAIMS

What is claimed is:

1. Anhydrous, hydrated, or solvated forms of a compound of Formula I,



2. The compound of claim 1, wherein the compound is the anhydrate form.
3. The compound of claim 2, wherein the compound has a decomposition temperature of about 240-250°C.
4. A crystalline form of anhydrous form 1 of (2*S*,4*S*)-4-fluoro-1-[4-fluoro-β-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile *p*-toluenesulfonic acid salt characterized by a powder x-ray diffraction pattern comprising at least one of the following peaks:

Two theta (deg)*	d-spacing (angstroms)
6.1 ± 0.2	14.4 ± 0.5
6.4 ± 0.2	13.9 ± 0.5
7.7 ± 0.2	11.5 ± 0.3
22.2 ± 0.2	4.0 ± 0.1
24.7 ± 0.2	3.6 ± 0.1

\* Using copper K-alpha 1 radiation.

5. The crystalline form of claim 4 comprising two or more of the following peaks:

Two theta (deg)*	d-spacing (angstroms)
$6.1 \pm 0.2$	$14.4 \pm 0.5$
$6.4 \pm 0.2$	$13.9 \pm 0.5$
$7.7 \pm 0.2$	$11.5 \pm 0.3$
$22.2 \pm 0.2$	$4.0 \pm 0.1$
$24.7 \pm 0.2$	$3.6 \pm 0.1$

\* Using copper K-alpha 1 radiation.


6. The crystalline form of claim 4 wherein the powder x-ray diffraction pattern is substantially similar to the pattern in Figure 1.
7. A pharmaceutical composition comprising a compound as claimed in claims 1-6.
8. A pharmaceutical composition comprising:  
anhydrous form 1 of (2*S*,4*S*)-4-fluoro-1-[4-fluoro- $\beta$ -(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile *p*-toluenesulfonic acid salt.
9. The pharmaceutical composition of claim 8 further comprising one or more hydrated form of (2*S*,4*S*)-4-fluoro-1-[4-fluoro- $\beta$ -(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile *p*-toluenesulfonic acid salt.
10. The pharmaceutical composition of claim 8 further comprising one or more solvated form of (2*S*,4*S*)-4-fluoro-1-[4-fluoro- $\beta$ -(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile *p*-toluenesulfonic acid salt.
11. The pharmaceutical composition of claim 8 further comprising one or more amorphous form of (2*S*,4*S*)-4-fluoro-1-[4-fluoro- $\beta$ -(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile *p*-toluenesulfonic acid salt.
12. The pharmaceutical composition as claimed in claims 7-11 further comprising one or more pharmaceutically acceptable carrier, diluent, or excipient.
13. A method for the treatment or prophylaxis of metabolic disorders, gastrointestinal disorders, viral disorders, autoimmune disorders, dermatological or mucous membrane disorders, compliment mediated disorders, inflammatory disorders, and psychosomatic, depressive, and neuropsychiatric disorders comprising administering a compound as claimed in any of claims 1 to 6.

14. The method of claim 13 wherein the disorder is diabetes, obesity, hyperlipidemia, psoriasis, intestinal distress, constipation, encephalomyelitis, glomerulonephritis, lipodystrophy, tissue damage, HIV infection, allergies, inflammation, arthritis, transplant rejection, high blood pressure, congestive heart failure, tumors, or stress-induced abortion.
15. A compound as claimed in any one of claims 1 to 6 for use in therapy.

# **AMENDED CLAIMS**

[received by the International Bureau on 17 November 2004 (17.11.04);  
Claim 3 amended; (1 page)]

1. Anhydrous, hydrated, or solvated forms of a compound of Formula I



2. The compound of claim 1, wherein the compound is the anhydrate form.
3. The compound of claim 2, wherein the compound has a decomposition temperature of about 240-250°C when heated at 10°/minute.
4. A crystalline form of anhydrous form 1 of (2S,4S)-4-fluoro-1-[4-fluoro-β-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile *p*-toluenesulfonic acid salt characterized by a powder x-ray diffraction pattern comprising at least one of the following peaks:

Two theta (deg) <sup>a</sup>	d-spacing (angstroms)
6.1 ± 0.2	14.4 ± 0.5
6.4 ± 0.2	13.9 ± 0.5
7.7 ± 0.2	11.5 ± 0.3
22.2 ± 0.2	4.0 ± 0.1
24.7 ± 0.2	3.6 ± 0.1

<sup>a</sup> Using copper K-alpha 1 radiation.